Investigational drug · Phase 3
Vamikibart
Also called: RO7200220
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Uveitic Macular Edema.
Phase 3Last checked: Nov 20, 2026Latest source record: Apr 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
5
Any phase or sponsor naming "Vamikibart"
First trial start
2023
Jan 9, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Vamikibart", any sponsor or status.
Conditions studied
As listed on its trial records.
- Uveitic Macular Edema
Approved drugs for the same conditions: Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "Vamikibart" as an intervention, largest first.
- A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular EdemaPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05151731 · 394 participants · Start Dec 31, 2021 · Primary completion Nov 6, 2024
Drug: Vamikibart; Ranibizumab · For: Diabetic Macular Edema
Sites: Arcadia, California; Poway, California; Sacramento, California · 74 sites in all
- Vamikibart in Participants With Uveitic Macular EdemaPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05642325 · 256 participants · Start Mar 23, 2023 · Primary completion May 7, 2025
Drug: Vamikibart · For: Uveitic Macular Edema
Sites: Phoenix, Arizona; Sun City, Arizona; Fullerton, California · 94 sites in all
- A Study to Investigate Vamikibart in Participants With Uveitic Macular EdemaPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05642312 · 245 participants · Start Jan 9, 2023 · Primary completion Dec 9, 2024
Drug: Vamikibart · For: Uveitic Macular Edema
Sites: Los Angeles, California; Lakewood, Colorado; St. Petersburg, Florida · 77 sites in all
- A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular EdemaPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05151744 · 187 participants · Start Dec 17, 2021 · Primary completion Apr 17, 2024
Drug: Vamikibart; Ranibizumab · For: Diabetic Macular Edema
Sites: Arcadia, California; Torrance, California; Walnut Creek, California · 38 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06771271 · 85 participants · Start Jul 22, 2019 · Primary completion Nov 13, 2023
Drug: RO7200220; Ranibizumab · For: Diabetic Macular Edema; Uveitic Macular Edema
Sites: Beverly Hills, California; Oxnard, California; Palm Desert, California · 19 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Intravitreal Interleukin 6 Inhibitors for Uveitic Macular Edema.
Llop SM, Narayan SL · JAMA Ophthalmol 2026
- Interleukin 6 Inhibition With Vamikibart for Uveitic Macular Edema: The Phase 1 DOVETAIL Nonrandomized Clinical Trial.
Sharma S, Lin P, Hu A, et al. · JAMA Ophthalmol 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.